Asset profile
Brentuximab Vedotin
Antibody–drug conjugate
Evidence outlook · lead readout
NCT04609566 · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04609566: This was a 161-participant, open-label, single-arm study with no comparator or randomization. Its primary endpoint was tumor response by RECIST v1.1, but results have not been posted, so there is no comparative evidence of benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.